

Examiner-Initiated Interview Summary	Application No. 10/656,838	Applicant(s) CHENG ET AL.	
	Examiner Leigh C. Maier	Art Unit 1623	

All Participants:

(1) Leigh C. Maier.

(2) Carl Morales.

Status of Application: _____

(3) _____

(4) _____

Date of Interview: 17 May 2007

Time: _____

Type of Interview:

- ☒ Telephonic
☐ Video Conference
☐ Personal (Copy given to: ☐ Applicant ☐ Applicant's representative)

Exhibit Shown or Demonstrated: ☐ Yes ☐ No
 If Yes, provide a brief description:

Part I.

Rejection(s) discussed:

Claims discussed:

3

Prior art documents discussed:

newly issued Wang et al (US 7,141,540)

Part II.

SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED:

See Continuation Sheet

Part III.

- ☒ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability.
☐ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.

(Examiner/SPE Signature)

(Applicant/Applicant's Representative Signature – if appropriate)

Continuation of Substance of Interview including description of the general nature of what was discussed: Exr indicated that claims were essentially in condition for allowance. However, upon updating the search exr found newly issued '540. This reference discloses linear polymers having pendant cyclodextrins and covalently attached "targeting moieties." The targeting moieties are described in such a way as to overlap with the instant "therapeutic agents." As in Gonzalez, there would be no motivation to make the attachments cleavable under biological conditions. Such a limitation to claim 3 would overcome a potential rejection over Wang. Mr. Morales authorized addition of said limitation by examiner's amendment. Upon further consideration of the generic treatment claim (former claim 20), it was determined that such a method claim was acceptable and exr suggested addition of such a claim - new claim 46.